Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Conditions
Brief summary
This study collects information about complications and clinical response in cancer patients treated with anti-VEGF-related therapies. This study aims to observe side effects that may happen to patients with advanced cancer who are treated with anti-VEGF related therapy. This may help doctors learn if there are any relationships between these side effects and how the disease may respond to treatment.
Detailed description
PRIMARY OBJECTIVE: I. To explore the incidence of clinical complications associated with anti-VEGF-related therapies in cancer patients treated at Emory University and the University of Texas M.D. Anderson Cancer Center (MDACC). SECONDARY OBJECTIVES: I. To explore the correlation of clinical response rates to a novel blood pressure scoring system in cancer patients treated with anti-VEGF-related therapies. II. To explore the correlation of objective response to each toxicity grade 3 or higher in cancer patients treated with anti-VEGF-related therapies. III. To investigate the validity of a novel multi-parameter-based blood pressure scoring system and to determine if the new scoring method is concordant with the current Common Terminology Criteria for Adverse Events (CTCAE) method. OUTLINE: Patients' medical records are reviewed.
Interventions
OTHERElectronic Health Record Review
Medical records are reviewed
Sponsors
M.D. Anderson Cancer Center
Study design
Observational model
CASE_ONLY
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients must be able to understand and be willing to sign a written informed consent document * Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of grade 3+ adverse events (AE) at least possibly related to anti-VEGF-related treatment (overall and each type separately) | Up to 5 years | For each toxicity, will estimate the odds ratio, associated 95% confidence interval and p-value. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORNicolas L Palaskas
M.D. Anderson Cancer Center
Outcome results
None listed